When was Incyte founded?

Incyte was founded in 1991 and raised its 1st funding round 22 years after it was founded.

Where is Incyte located?

Incyte is headquartered in Wilmington, United States. It is registered at Wilmington, Delaware.

How many employees does Incyte have?

As of Aug 31, 2026, the latest employee count at Incyte is 3524.

Is Incyte a funded company?

Incyte is a funded company, having raised a total of $***** in its 1st and only funding round, a Post IPO round on Nov 14, 2013.

When was the latest funding round of Incyte?

Incyte's latest funding was a $***** Post IPO round on Nov 14, 2013, with participation from 0 investor.

What is the annual revenue of Incyte?

Annual revenue of Incyte is more than $1B as on Dec 31, 2025

Where does Incyte rank among its competitors?

Incyte ranks 50th amongst 3468 active competitors, of which 1154 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Sana Biotechnology, which secured $25M in Aug, 2026.

Who are the top competitors of Incyte?

Incyte's top competitors include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Among them, Sana Biotechnology secured the most recent funding round in August, 2026.

Incyte - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of small molecules for the treatment of different cancer and skin diseases. The company provides Jakafi to treat polycythemia vera (PV) and myelofibrosis (MF). Its product pipeline includes Pemazyre for Cholangiocarcinoma3 Monjuv for lymphoma, Iclusig for chronic myeloid leukemia, ruxolitinib for chronic GVHD, and others.

Website: incyte.com
Social
Email ID: *****@incyte.com
Phone Number: +1 **********
Registered Address: Wilmington, Delaware

Key Metrics

Founded Year

1991

Location

Wilmington, United States

Stage

Public

Latest Funding Round

Post IPO, Nov 14, 2013, $*****

Investors

BB Biotech & 6 more

Ranked

50^th among 3468 active competitors

Annual Revenue

$1B+ as on Dec 31, 2025

Employee Count

3,524 as on Aug 31, 2026

Investment & Acquisitions

Vega Therapeutics & 5 more

Similar Companies

BeiGene & 741 more

Exit Details

Public

View Incyte's full profile

Incyte is associated with 3 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Incyte Biosciences International Sàrl CIN: 0800.993.831 , Belgium, Active	Apr 01, 2023	-	-	-
Incyte Corp CIN: 879169 , United States, Active	Apr 07, 1991	$1B+ (As on Dec 31, 2025)	-	-
Incyte Corporation CIN: 943136539 , United States, Active	Dec 26, 999	-	1903 (As on Dec 31, 2024)	-

Incyte got listed on Nov 04, 1993.

Click here to take a look at Incyte's IPO in detail

Incyte has raised funding over 1 round. Incyte has 7 institutional investors.

Here is the list of recent funding rounds of Incyte:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 14, 2013	7314801	Post IPO	6051151	6487790	2493589	8598531

Access funding benchmarks and valuations. Sign up today!

View details of Incyte's funding rounds and investors

Incyte's employee count trend

Incyte has 3,524 employees as of Aug 26. Here is Incyte's employee count trend over the years:

Uncover Incyte's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Incyte include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of Incyte, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	81/100
2nd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, T. Rowe Price & 13 others	81/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 18 others	74/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
5th	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
6th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
7th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	72/100
9th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	F-Prime Capital, Khosla Ventures & 23 others	72/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
50th	Incyte 1991, Wilmington (United States), Public	Developer of small molecules for the treatment of different cancer and skin diseases	-	BB Biotech, Tekla Capital Management & 5 others	66/100

Get insights and benchmarks for competitors of 2M+ companies! Sign up today!

Looking for more details on Incyte's competitors? Click here to see the top ones

Incyte has made 2 investments in companies including MorphoSys and Agenusbio. Incyte has also acquired 4 companies including Vega Therapeutics and Escient Pharmaceuticals.

Here is the list of investments & acquisitions:

Filter this list

Date of Investment/Acquisition	Type	Company Name	Founded Year	Location
Jun 08, 2026	Acquisition	Vega Therapeutics	2018	San Francisco (United States)
Apr 23, 2024	Acquisition	Escient Pharmaceuticals	2017	San Diego (United States)
Oct 03, 2022	Acquisition	Villaris Therapeutics	2019	Cary (United States)